Zoetis Inc. (ZTS) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript

Zoetis guides to 3%–5% organic operational revenue growth in 2026 (3.5% midpoint) versus 6% organic growth in 2025, signaling a notable deceleration. Management expects paras to lead growth, pain to return to growth, derm to face increased competition, diagnostics to remain strong, and livestock to continue as a bright spot (historical growth ~2%–4%).

Analysis

Derm franchise share loss is already filtering into margin and mix dynamics; expect management to defend share with incremental promotional spend and channel incentives that compress SG&A/Gross margins for at least the next two quarters. That spending cycle creates a second-order benefit for distributors and contract-packers who will see higher order volatility and margin pressure—look for working-capital drag in the near term and elevated inventory churn at players like CVET/PDCO.

Diagnostics and livestock act as structural stabilizers: diagnostics provide recurring consumables demand with higher gross-margin stickiness, and livestock exposure hedges companion-animal cyclicality if protein economics stay supportive. This bifurcation increases the optionality of cross-sell bundles (vaccines + diagnostics) and makes Zoetis more resilient to a single-franchise shock; vendors of reagents/instruments (IDXX) and specialized CRO/CMO partners stand to gain as diagnostics scale.

Key risks are asymmetric: an accelerated wave of generic/OTC entrants into dermatology could compress core pricing beyond current expectations, while an idiosyncratic livestock disease or macro shock to protein demand could flip livestock from tailwind to headwind within 6-12 months. Near-term catalysts that would re-rate the story positively are measurable uplift in pain-product uptake and margin expansion from higher-margin diagnostics within 2-4 quarters; meaningful downside would be visible within the next earnings cycle if promotional intensity rises materially.

Key Decisions for Investors

• Long ZTS (12-month horizon): buy a 12-month call spread to capture diagnostics/livestock optionality while capping premium. Target 15-25% upside if diagnostics margins accelerate; cut to flat on an 8-10% adverse move or if SG&A ramps 200-300bps above consensus in next print.
• Pair trade — Long ZTS / Short ELAN (6-12 months): expect Zoetis to outperform if diagnostics and companion-animal franchises hold while ELAN remains more exposed to cyclical livestock volatility. Position size 1:1 notional, target 10-20% relative outperformance, stop if ELAN announces a credible turnaround or ZTS misses multiple pipeline uptake metrics.
• Long IDEXX (IDXX) or diagnostic-services exposure (9-12 months): buy outright or buy-call spread to play higher consumables demand from expanding animal diagnostics. Risk/reward asymmetric: limited downside in consumable annuity, 20%+ upside if diagnostic penetration accelerates.
• Tactical: sell into strength post-earnings (30-60 days): if ZTS prints conservative growth but reiterates investment in derm defense, use the pop to trim long exposure or write covered calls to harvest elevated IV and fund longer-dated upside exposure.